Clinical observation of long-acting injectable risperidone treatment on 41 schizophrenia patients
NING Bu
LIU Xiang-xin
QUAN Dong-ming
LIN Yong-qiang
FENG Mei-zhen
LIU Wu-han
JIA Fu-jun
Abstract：Objective: To investigate the remission and relapse of long-acting injectable risperidone (RLAI) long-term treatment on schizophrenia patients. Methods:This study integrated retrospective investigation and prospective observation. Schizophrenia patients who had been treated with RLAI for 3 months and meet the in-clusion criteria were enrolled into the observation phase. Patients were followed up every three months until relapse or dropout occurred. Retrospective investigation was performed the data of patients in the prior to three months treatment. The efficacy endpoints were remission rate, relapse rate, CGI-S and PSP. In the observation phase, pa-tients were treated in natural clinical setting and there was no interference from investigators. Results : At present, 41 schizophrenia patients were enrolled. 5 (12.20%) patients discontinued due to economic difficulty, other 36 patients(100%) meet the remission criteria after 9-month treatment . No relapse occurred during treatment period in 41 patients and the relapse rate was 0%. Adverse events occurred in 10 patients (24.49%), and majority (90.00%) of them were mild. The LAIR treatment was not interrupted by the adverse events. Conclusion : Patients achieved a high remission rate and a low relapse rate after 9-month RLAI treatment.
Keywords：schizophrenialong-acting injectable risperidone (RLAI)remissionrelapse
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 1316-1319,1332 )